Clinical trial
Efficacy and Safety of Refralon in Patients With Recurrent Atrial Fibrillation and Atrial Flutter After Catheter Ablation.
NCT05456204 is registered in ClinicalTrials.gov with National Medical Research Center for Cardiology, Ministry of Health of Russian Federation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy and Safety of Refralon in Patients With Recurrent Atrial Fibrillation and Atrial Flutter After Catheter Ablation.
- Lead sponsor
- National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
- Phase
- Not applicable
- Overall status
- Completed
- Start date
- February 15, 2022
- Completion date
- June 30, 2024
- Enrollment
- 120 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
atrium; fibrillation, atrium; flutter